WHO recommends that pre-exposure prophylaxis (PrEP) be offered as an additional prevention choice for HIV-negative individuals at substantial risk of HIV infection as part of combination prevention approaches.
HIV drug resistance has been rarely reported among PrEP users who tested HIV positive i...n randomized controlled trials or open-label studies. However, PrEP-selected HIV drug resistance could potentially negatively impact the effectiveness of treatment options among PrEP users who acquire HIV, since there is a potential for overlapping resistance profiles between antiretroviral drugs used for both PrEP and first-line antiretroviral therapy.
more
Guidelines
June 2017
HIV strategic information for impact
HIV-related advocacy evaluation training for civil society organisations
Examen du rôle de la société civile dans le plaidoyer et le lobbying en faveur de l'application de la politique de santé au Kenya
African Population Studies Vol 25, 1 (Supplement) 2011
http://aps.journals.ac.za
A practical toolkit for young people who are passionate about advancing HIV and sexual and reproductive health and rights through national advocacy in the post-2015 agenda.
UNAIDS 2017 / Reference
Generating evidence for policy and action on HIV and social protection
Translating Community Research Into Global Policy Reform For National Action: A Checklist For Community Engagement To Implement The WHO Consolidated Guideline On The Sexual And Reproductive Health And Rights Of Women Living With HIV
3rd edition | December 2018
Policy
July 2012
Working Paper No. 3